Establishment Labs Q4 2025 Earnings Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy ESTA?
Source: seekingalpha
- Significant Revenue Growth: Establishment Labs reported fourth-quarter revenue of $64.6 million for 2025, representing a 45.2% year-over-year increase, with U.S. Motiva sales contributing $17.3 million, highlighting the company's strong market performance and growth potential.
- Gross Margin Improvement: The gross margin exceeded 70% for the second consecutive quarter, reaching 70.5%, up from 68.5% last year, reflecting successful cost management and operational efficiency, with expectations for further margin enhancement in the future.
- Rapid Market Share Expansion: The company achieved approximately 20% augmentation market share in the U.S. within a single year, indicating that product innovation and strong demand have significantly driven sales growth.
- Optimistic 2026 Outlook: Management provided guidance for 2026 revenue of $264 million to $266 million, representing a growth rate of 25% to 26%, and plans to expand the U.S. sales force to further enhance market penetration and product adoption.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ESTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ESTA
Wall Street analysts forecast ESTA stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 76.095
Low
75.00
Averages
82.88
High
90.00
Current: 76.095
Low
75.00
Averages
82.88
High
90.00
About ESTA
Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Establishment Labs Q4 2025 Earnings Highlights
- Significant Revenue Growth: Establishment Labs reported fourth-quarter revenue of $64.6 million for 2025, representing a 45.2% year-over-year increase, with U.S. Motiva sales contributing $17.3 million, highlighting the company's strong market performance and growth potential.
- Gross Margin Improvement: The gross margin exceeded 70% for the second consecutive quarter, reaching 70.5%, up from 68.5% last year, reflecting successful cost management and operational efficiency, with expectations for further margin enhancement in the future.
- Rapid Market Share Expansion: The company achieved approximately 20% augmentation market share in the U.S. within a single year, indicating that product innovation and strong demand have significantly driven sales growth.
- Optimistic 2026 Outlook: Management provided guidance for 2026 revenue of $264 million to $266 million, representing a growth rate of 25% to 26%, and plans to expand the U.S. sales force to further enhance market penetration and product adoption.
See More
Establishment Labs Q4 Earnings Exceed Expectations
- Earnings Highlights: Establishment Labs reported a Q4 GAAP EPS of -$0.09, beating expectations by $0.13, indicating a trend towards improved profitability for the company.
- Revenue Growth: Q4 revenue reached $64.62M, a 45.2% year-over-year increase, exceeding market expectations by $0.5M and reflecting strong performance amid robust market demand.
- Future Guidance: The company projects 2026 revenue between $264M and $266M, representing a 25.1% to 26.0% increase over 2025, showcasing sustained growth potential and market confidence.
- Long-term Growth Outlook: Revenue for 2027 is expected to grow by at least 25%, indicating the company's commitment to expanding market share and enhancing profitability in the coming years.
See More
Vanguard Health Care ETF Sees 14.9% Insider Buying in Holdings
- Insider Buying Ratio: The Vanguard Health Care ETF (VHT) shows that 14.9% of its holdings have experienced insider buying in the past six months, indicating strong confidence from executives that could positively influence investor sentiment.
- Teleflex Activity: Teleflex (TFX), comprising 0.07% of VHT, has seen 5 directors and officers purchase shares in the last six months, suggesting internal optimism about its stock price, which may bolster market confidence in the company.
- Establishment Labs Activity: Establishment Labs (ESTA), ranked 216th in VHT with a holding value of approximately $3,464,977, recently had 2 directors and officers file Form 4s indicating purchases, reflecting a positive outlook on the company's future growth.
- ETF Holding Value: The Vanguard Health Care ETF holds a total of $13,702,466 worth of TFX, making it the 106th largest holding, showcasing the ETF's strategic investment in the healthcare sector, which may attract more investors focused on this industry.
See More
Establishment Labs CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
- Executive Presentation: Establishment Labs CEO Peter Caldini and CFO Raj Denhoy will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 9:45 AM PT, showcasing the company's latest advancements in women's health.
- Live Webcast: The presentation will be available via a live webcast on Establishment Labs' investor relations website, allowing global investors to gain real-time insights into the company's strategic direction and market dynamics, thereby enhancing investor confidence.
- Product Innovation: Establishment Labs has delivered over four million Motiva® devices since 2010, establishing the company as a leader in breast aesthetics and reconstruction, significantly improving patient satisfaction and safety standards.
- Technological Strength: With over 200 patent applications and more than 100 scientific studies, the company demonstrates its innovative capabilities and competitive edge in the women's health technology sector.
See More
Establishment Labs CEO to Present at 2026 J.P. Morgan Healthcare Conference
- Executive Presentation Schedule: Establishment Labs CEO Peter Caldini and CFO Raj Denhoy will present at the J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's latest advancements in women's health, which is expected to attract investor interest.
- Technology Innovation Showcase: The company is dedicated to improving women's health through science and engineering, offering breast aesthetics and reconstruction solutions in over 90 countries, demonstrating its extensive influence in the global market.
- Product Delivery Achievement: Since 2010, Establishment Labs has delivered over 4 million Motiva® devices, establishing a new standard for safety and patient satisfaction, further solidifying its leadership position in the medical device industry.
- R&D Strength: With over 200 patent applications and more than 100 scientific studies, the company demonstrates its ongoing innovation capabilities in breast health, which is expected to drive future market growth.
See More
Establishment Labs Submits Motiva Implants for FDA Approval in Breast Reconstruction
- FDA Approval Expansion: Establishment Labs has submitted Motiva implants for breast reconstruction approval, marking a significant advancement in women's health and expected to meet the urgent market demand for innovative reconstruction technologies.
- Clinical Study Results: The Motiva U.S. IDE study, conducted at 17 U.S. centers and one European center, included 274 patients, demonstrating the product's effectiveness in breast reconstruction, which could enhance the company's market share in the medical technology sector.
- Technological Innovation: Motiva implants feature a SmoothSilk® surface designed for enhanced biocompatibility and reduced inflammation, which is expected to improve patient satisfaction and surgical outcomes, further solidifying the company's leadership position in the industry.
- Market Potential: Since receiving approval for breast augmentation in 2024, over 60,000 Motiva implants have been sold in the U.S., indicating strong market demand, and the recent approval for reconstruction indications is anticipated to further drive sales growth.
See More
Establishment Labs Q4 2025 Earnings Highlights
- Significant Revenue Growth: Establishment Labs reported fourth-quarter revenue of $64.6 million for 2025, representing a 45.2% year-over-year increase, with U.S. Motiva sales contributing $17.3 million, highlighting the company's strong market performance and growth potential.
- Gross Margin Improvement: The gross margin exceeded 70% for the second consecutive quarter, reaching 70.5%, up from 68.5% last year, reflecting successful cost management and operational efficiency, with expectations for further margin enhancement in the future.
- Rapid Market Share Expansion: The company achieved approximately 20% augmentation market share in the U.S. within a single year, indicating that product innovation and strong demand have significantly driven sales growth.
- Optimistic 2026 Outlook: Management provided guidance for 2026 revenue of $264 million to $266 million, representing a growth rate of 25% to 26%, and plans to expand the U.S. sales force to further enhance market penetration and product adoption.
See More
Establishment Labs Q4 Earnings Exceed Expectations
- Earnings Highlights: Establishment Labs reported a Q4 GAAP EPS of -$0.09, beating expectations by $0.13, indicating a trend towards improved profitability for the company.
- Revenue Growth: Q4 revenue reached $64.62M, a 45.2% year-over-year increase, exceeding market expectations by $0.5M and reflecting strong performance amid robust market demand.
- Future Guidance: The company projects 2026 revenue between $264M and $266M, representing a 25.1% to 26.0% increase over 2025, showcasing sustained growth potential and market confidence.
- Long-term Growth Outlook: Revenue for 2027 is expected to grow by at least 25%, indicating the company's commitment to expanding market share and enhancing profitability in the coming years.
See More
Vanguard Health Care ETF Sees 14.9% Insider Buying in Holdings
- Insider Buying Ratio: The Vanguard Health Care ETF (VHT) shows that 14.9% of its holdings have experienced insider buying in the past six months, indicating strong confidence from executives that could positively influence investor sentiment.
- Teleflex Activity: Teleflex (TFX), comprising 0.07% of VHT, has seen 5 directors and officers purchase shares in the last six months, suggesting internal optimism about its stock price, which may bolster market confidence in the company.
- Establishment Labs Activity: Establishment Labs (ESTA), ranked 216th in VHT with a holding value of approximately $3,464,977, recently had 2 directors and officers file Form 4s indicating purchases, reflecting a positive outlook on the company's future growth.
- ETF Holding Value: The Vanguard Health Care ETF holds a total of $13,702,466 worth of TFX, making it the 106th largest holding, showcasing the ETF's strategic investment in the healthcare sector, which may attract more investors focused on this industry.
See More
Establishment Labs CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
- Executive Presentation: Establishment Labs CEO Peter Caldini and CFO Raj Denhoy will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 9:45 AM PT, showcasing the company's latest advancements in women's health.
- Live Webcast: The presentation will be available via a live webcast on Establishment Labs' investor relations website, allowing global investors to gain real-time insights into the company's strategic direction and market dynamics, thereby enhancing investor confidence.
- Product Innovation: Establishment Labs has delivered over four million Motiva® devices since 2010, establishing the company as a leader in breast aesthetics and reconstruction, significantly improving patient satisfaction and safety standards.
- Technological Strength: With over 200 patent applications and more than 100 scientific studies, the company demonstrates its innovative capabilities and competitive edge in the women's health technology sector.
See More
Establishment Labs CEO to Present at 2026 J.P. Morgan Healthcare Conference
- Executive Presentation Schedule: Establishment Labs CEO Peter Caldini and CFO Raj Denhoy will present at the J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's latest advancements in women's health, which is expected to attract investor interest.
- Technology Innovation Showcase: The company is dedicated to improving women's health through science and engineering, offering breast aesthetics and reconstruction solutions in over 90 countries, demonstrating its extensive influence in the global market.
- Product Delivery Achievement: Since 2010, Establishment Labs has delivered over 4 million Motiva® devices, establishing a new standard for safety and patient satisfaction, further solidifying its leadership position in the medical device industry.
- R&D Strength: With over 200 patent applications and more than 100 scientific studies, the company demonstrates its ongoing innovation capabilities in breast health, which is expected to drive future market growth.
See More
Establishment Labs Submits Motiva Implants for FDA Approval in Breast Reconstruction
- FDA Approval Expansion: Establishment Labs has submitted Motiva implants for breast reconstruction approval, marking a significant advancement in women's health and expected to meet the urgent market demand for innovative reconstruction technologies.
- Clinical Study Results: The Motiva U.S. IDE study, conducted at 17 U.S. centers and one European center, included 274 patients, demonstrating the product's effectiveness in breast reconstruction, which could enhance the company's market share in the medical technology sector.
- Technological Innovation: Motiva implants feature a SmoothSilk® surface designed for enhanced biocompatibility and reduced inflammation, which is expected to improve patient satisfaction and surgical outcomes, further solidifying the company's leadership position in the industry.
- Market Potential: Since receiving approval for breast augmentation in 2024, over 60,000 Motiva implants have been sold in the U.S., indicating strong market demand, and the recent approval for reconstruction indications is anticipated to further drive sales growth.
See More
